Lung Cancer
Volume 70, Issue 1 , Pages 57-62 , October 2010

Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: A systematic review and meta-analysis

  • Hao Lin

      Affiliations

    • Department of Oncology, Huashan Hospital, Fudan University, Shanghai 200040, China
    • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200040, China
    • These two authors contribute equally to this work.
    • ,
  • Jingwei Jiang

      Affiliations

    • Department of Oncology, Huashan Hospital, Fudan University, Shanghai 200040, China
    • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200040, China
    • These two authors contribute equally to this work.
    • ,
  • Xiaohua Liang

      Affiliations

    • Department of Oncology, Huashan Hospital, Fudan University, Shanghai 200040, China
    • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200040, China
    • Corresponding Author InformationCorresponding author at: Department of Oncology, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Road, Shanghai 200040, China. Tel.: +86 21 52887162; fax: +86 21 62489191.
    • ,
  • XinLi Zhou

      Affiliations

    • Department of Oncology, Huashan Hospital, Fudan University, Shanghai 200040, China
    • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200040, China
    • ,
  • Ruofan Huang

      Affiliations

    • Department of Oncology, Huashan Hospital, Fudan University, Shanghai 200040, China
    • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200040, China

Received 18 July 2009 ,Revised 10 January 2010 ,Accepted 12 January 2010.

References 

  1. National Cancer Institute SEER data. Available at: http://seer.cancer.gov/statistics/. Accessed June 20; 2009.
  2. Rossi A, Maione P, Gridelli C. Cetuximab in advanced non-small cell lung cancer. Crit Rev Oncol Hematol. 2006;59(2):139–149
  3. Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res. 2005;11(2 (Pt 1)):795–805
  4. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial). J Clin Oncol. 2003;21(12):2237–2246
  5. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al. A phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol. 2002;21:292a;[abstract 1166]
  6. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol. 2004;22(16):3238–3247
  7. Shepherd FA, Pereira J, Ciuleanu TE. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J Clin Oncol. 2004;22(14S):7022;[abstract]
  8. Stinchcombe TE, Socinski MA. Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?. Oncologist. 2008;13(9):933–944
  9. Tsuchihashi Z, Khambata-Ford S, Hanna N, Jänne PA. Responsiveness to cetuximab without mutation in EGFR. N Engl J Med. 2005;353(2):208–209
  10. Steiner P, Joynes C, Bassi R, Wang S, Tonra JR, Hadari YR, et al. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Clin Cancer Res. 2007;13(5):1540–1551
  11. Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D, Alam Y, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol. 2007;25(36):5777–5784
  12. Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, Mennecier BC, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol. 2008;19(2):362–369
  13. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373(9674):1525–1531
  14. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim W, Hermann RC, et al. Overall survival (OS) results from the phase III trial BMS 099: cetuximab+taxane/carboplatin as 1st-line treatment for advanced NSCLC. J Thorac Oncol. 2008;3(Suppl.):S305
  15. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996;17(1):1–12
  16. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–2834
  17. Deeks J, Altman D, Bradburn M. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In:  Egger M,  Smith GR,  Altman DG editor. Systematic reviews in health care: meta-analysis in context. 2nd. ed.. London, UK: BMJ Books; 2001;p. 285–312
  18. Borghaei H, Langer CJ, Millenson M, Ruth KJ, Litwin S, Tuttle H, et al. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol. 2008;3(11):1286–1292
  19. Robert F, Blumenschein G, Herbst RS, Fossella FV, Tseng J, Saleh MN, et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol. 2005;23(36):9089–9096
  20. Thienelt CD, Bunn PA, Hanna N, Rosenberg A, Needle MN, Long ME, et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2005;23(34):8786–8793
  21. Belani CP, Schreeder MT, Steis RG, Guidice RA, Marsland TA, Butler EH, et al. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer. 2008;113(9):2512–2517
  22. Bradford DS, Socinski MA, LaRocca RV, Hensing TA, Bordoni RE. Phase II trial of carboplatin plus cetuximab for the treatment of stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol. 2007;25(18S):18005
  23. Borghaei H, Langer CJ, Millenson M, Tuttle H, Seldomridge J, Rovito M, et al. Phase II trial of cetuximab (C225) in combination with monthly carboplatin (Cb) and weekly paclitaxel (Pac) in patients with advanced NSCLC: promising early results. J Clin Oncol. 2008;26(15S):8104
  24. Spigel DR, Greco FA, Burris HA, Yardley DA, Vazquez ER, Hainsworth JD. Docetaxel, gemcitabine, and cetuximab in untreated advanced non-small cell lung cancer. J Thor Oncol. 2007;2(Suppl. 4):S740–S741
  25. Gridelli C, Morabito A, Gebbia V, Mencoboni M, Carrozza F, Viganò MG, et al. Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: the cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer. 2010;67(1):86–92
  26. Socinski MA, Saleh MN, Trent DF, Dobbs TW, Zehngebot LM, Levine MA, et al. A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC). Ann Oncol. 2009;20(6):1068–1073
  27. Kim E. Docetaxel or pemetrexed with or without cetuximab in patients with recurrent or progressive non-small cell lung cancer. http://clinicaltrials.gov. NLM Identifer NCT00095199.
  28. Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G. The biological properties of cetuximab. Crit Rev Oncol Hematol. 2008;68(2):93–106
  29. Lilenbaum RC. The evolving role of cetuximab in non-small cell lung cancer. Clin Cancer Res. 2006;12(14 Pt 2):4432s–4435s
  30. Morgensztern D, Govindan R. Is there a role for cetuximab in non small cell lung cancer?. Clin Cancer Res. 2007;13(15 (Pt 2)):4602s–4605s
  31. American Society of Clinical Oncology/FDA Lung Cancer Endpoints workshop: lung cancer endpoints. 2009;Available at http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm117709.htm#lung, accessed June 20, 2009
  32. Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Woytowitz D, et al. Lung cancer symptoms with cetuximab/taxane/carboplatin in first-line advanced NSCLC: analysis of the BMS099 trial. J Clin Oncol. 2009;27(15S):e19011
  33. Berlin J, Van Cutsem E, Peeters M, Hecht JR, Ruiz R, Wolf M, et al. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): a pooled analysis of five clinical trials. J Clin Oncol. 2007;25(18S):4134
  34. Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu L, Dakhil S, et al. K-RAS mutations (MT) and EGFR-related markers as potential predictors of the cetuximab benefit in 1st line advanced NSCLC: results from the BMS099 study. J Thorac Oncol. 2008;3(Suppl.):S304
  35. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290(16):2149–2158
  36. Hirsch FR, Bunn PA. Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?. J Clin Oncol. 2005;23(36):9044–9047
  37. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 2008;26(20):3351–3357
  38. Niu G, Li Z, Xie J, Le QT, Chen X. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med. 2009;50(7):1116–1123
  39. Oden-Gangloff A, Di Fiore F, Bibeau F, Lamy A, Bougeard G, Charbonnier F, et al. TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer. 2009;100(8):1330–1335
  40. Levy EM, Sycz G, Arriaga JM, Barrio MM, von Euw EM, Morales SB, et al. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells. Innate Immun. 2009;15(2):91–100
  41. Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, et al. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res. 2008;14(23):7884–7895
  42. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol. 2009;27(7):1122–1129
  43. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26(35):5705–5712

PII: S0169-5002(10)00011-5

doi: 10.1016/j.lungcan.2010.01.009

Lung Cancer
Volume 70, Issue 1 , Pages 57-62 , October 2010

Article Tools

* Image Usage & Resolution